The campaign is called #BustTheMyth and is aimed at patient education.
Hologic announced a new breast cancer awareness campaign titled #BustTheMyth, which (as the name implies) is focused on debunking several myths related to breast cancer. The patient education campaign provides information about commonly held beliefs connected to breast density and mammograms. It also aims to promote the necessity of getting breast exams, which are often skipped for a variety of reasons (anxiety, lack of time, or simply being unaware that an exam was important).
Two of the myths covered by the campaign are connected to family health history and breast density. Many women believe that since their family doesn’t have a history of breast cancer, they don’t need to worry. Also, it’s commonly believed that women with dense breast tissue can tell just by feeling them. Both of these myths are untrue and can result in women not getting mammograms in a timely manner.
In a press release, Hologic chairman, president, and CEO Steve MacMillan said, “As a leading women’s health organization, we are committed to supporting women at every stage of their health journey and that includes advocating for change and increasing awareness about the importance of breast cancer screening and early detection. There are many harmful myths about mammograms that keep women from understanding their risks and getting screened annually. We want to empower women with facts so they can prioritize themselves and take charge of their health with confidence.”
In the same press release, Hologic president of breast and skeletal health solutions added, “At Hologic, we are committed to continually advancing technology and improving patient outcomes across the continuum of breast health. But we know that world-class technology alone won’t decrease rates of death from breast cancer. It also takes empowering and practical education. The #BustTheMyth campaign adds to our extensive history of public outreach and reinforces our commitment to saving and improving more lives.”
In July of this year, Hologic announced that it had completed its acquisition of Endomagnetics Ltd, a UK-based developer of breast cancer surgery technologies.2
In a press release issued at the time, Anderson said, “We are thrilled to complete the acquisition of Endomag and are looking forward to working with our new colleagues to increase access to their innovative technologies, which complement and diversify our expanding interventional breast health portfolio. With our shared commitment to advancing women’s health globally, we are excited to improve outcomes for patients and, together with our customers, redefine the standard of care for breast cancer intervention.”
In the same press release, Endomag CEO Eric Mayes, PhD, said, “We are so proud of the company we built and the practice-changing breast surgery technologies that we developed following years of relentless research, innovation and deep engagement with clinicians. As we embark on this new journey with Hologic, I am filled with optimism about the opportunities for our team, our forthcoming innovations and our ability to impact even more women around the world.”
Yescarta Demonstrates Promise in Treating Relapsed/Refractory Large B-Cell Lymphoma
December 9th 2024Real-world evidence from the largest analysis of second-line treatment with Yescarta in 2022-2023 demonstrated a high overall survival rate in patients with relapsed/refractory large b-cell lymphoma.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.